Hoth Therapeutics Launches OpenClaw AI Platform to Speed Up Drug Discovery

Clinical-stage biopharmaceutical company Hoth Therapeutics announced the deployment of the OpenClaw™ AI platform to accelerate drug discovery and R&D workflows. The company said the platform will be used to improve R&D efficiency and speed up decision-making across stages including early research, candidate molecule screening, and data analysis, further reinforcing its AI-driven R&D capabilities.

Previously, Hoth disclosed multiple initiatives to expand its AI capabilities, including a collaboration with NVIDIA that aims to apply related technologies to areas such as predictive pharmacology and toxicity modeling, in order to improve risk assessment and optimization strategies during R&D. The company has also integrated the OpenAI API into its HT-KIT development workflow to support preclinical data analysis and molecule-related research tasks, enhancing the intelligence of its R&D toolchain.

Commentary: From partnering on GPU compute to adopting large-model APIs and now rolling out an in-house AI platform, Hoth is systematically building an R&D infrastructure spanning “data–models–applications.” Going forward, the key will be verifiable outcomes in specific programs—such as measurable gains in screening efficiency, candidate quality, and the speed of preclinical decision-making.